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Abstract
Mast cell tumor is one of the major cutaneous tumors in dogs. Though the etiology of 
MCTs is not completely understood, it becomes clear that approximately 10–20% MCTs 
express mutant KIT receptors with ligand‐independent phosphorylation. Tyrosine kinase 
inhibitors targeting KIT exert antitumor effects on malignant proliferation of mast cells 
with or without gene mutations. However, the efficacy of KIT inhibitors on dogs with 
MCTs has been limited. In this chapter, we would like to outline the general understand‐
ings of mast cells such as the process of its differentiation and proliferation, and what has 
been revealed regarding the mechanism of tumorigenesis and therapeutic approaches. 
In particular, KIT mutation‐related evidences and therapeutic approaches in the future 
are discussed.
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1. Introduction
Mast cells are originated from hematopoietic stem cells in bone marrow as similar to other 
granulocytes. However, mast cells are very unique because they are released from bone mar‐
row as undifferentiated progenitor cells to the circulation, and their final maturation is com‐
pleted in the peripheral tissues. We find mast cells in most of the tissues and organs in our 
body, particularly in interstitial connective tissues of each organ being close to blood vessels. 
Mast cells play crucial roles in innate immunity against parasites and microbes that is essen‐
tial for host defense in humans and animals. In acquired immunity, activation of mast cells is 
induced by cross‐linkage of IgE that binds to high‐affinity IgE receptors after antigen expo‐
sure. Moreover, some chemicals and toxins as well as physical (i.e., scratching and heat) and 
neurogenic stimuli trigger activation of mast cells. Various chemical mediators and cytokines 
are released from mast cells after their degranulation, and sometimes initiate allergic inflam‐
mation and itch sensation. In canine medicine, serious involvement of mast cells in allergic 
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diseases has been identified, and mast cells are estimated as the most important target in 
medical treatment of allergy. Although malignancies of mast cell are uncommon disorders 
in humans, veterinary clinicians frequently encounter mast cell tumors (MCTs) in dogs and 
cats. The frequency of cutaneous MCTs has been reported to reach 20% of all tumors raised 
in the skin of dogs. Most of the malignant mast cells existed in a mass have granules in their 
cytosol, containing pruritogens, inflammatory factors, and various proteases (Figure 1). In 
this chapter, recent information on both basics in mast cell biology and clinical approaches 
for canine MCTs is outlined.
2. Differentiation and proliferation of mast cells
2.1. Differentiation of mast cells
Mast cell progenitors are differentiated from pluripotent hematopoietic stem cells in bone 
marrow. Being different from other granulocytes, mast cells are transported by blood stream 
to peripheral tissues as mononuclear immature cells without granules in their cytosol [1]. In 
peripheral tissues, mast cell precursors complete their differentiation and distribution being 
ready for the host defense (Figure 2). According to characters of microenvironment of each 
peripheral tissue, final types of mature mast cells are altered. In the skin, they differenced into 
connective tissue‐type mast cells that include heparin proteoglycan and abundant granules 
in cytosol. Various kinds of proteases and chemical mediators are in granules of connective 
tissue‐type mast cells by which sever inflammation is induced when they are released at the 
affected sites. Heparin proteoglycan‐ positive mast cells can be detected with not only tolu‐
idine blue but also berberine sulfate and safranin O. In contrast, mast cells that reach to and 
invade in mucosal tissues differentiate into  mucosal‐type mast cells. Mucosal‐type mast cells 
include chondroitin sulfate as  proteoglycan, and cytosolic granules are very few. Chondroitin 
Figure 1. Typical histologic features of surgically removed canine MCTs stained with toluidine blue solution. A mass 
is consisted with numbers of differenced mast cells that show metachromasia. Connective tissues colored in light blue 
can be identified.
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sulfate‐positive mast cells are identified with alcian blue staining, but not with toluidine blue, 
berberine sulfate, or safranin O. Connective tissue‐type mast cells are found in the skin and 
connective tissues in various organs. On the other hand, mucosal‐type mast cells are differen‐
tiated in mucosa of the gastrointestinal tract.
2.2. Proliferation of mast cells
Factors that involve in mast cell proliferation are not fully understood. In mice, mast cells 
proliferate in response to interleukin (IL)‐3, IL‐9, and stem cell factor (SCF). Both IL‐6 and SCF 
are essential factors for proliferation and survival of human mast cells. Though less is known 
regarding development of canine mast cells, SCF has been reported to induce proliferation 
and survival, as well as migration and activation of canine mast cells [2, 3]. The IL dependency 
varies according to a species from which mast cells are derived. However, SCF is the most 
important factor for proliferation, differentiation, and survival of mast cells in humans and 
animals. SCF is the ligand for KIT receptors expressed on cell surface of mast cells. Since mast 
cells are differentiated from KIT‐positive cell lineage and KIT is retained on the surface of not 
only immature precursors but also mature mast cells, influence of SCF on mast cells must be 
crucial for their proliferation and differentiation. In fact, gain‐of‐function mutations in the 
KIT gene have been identified in mast cells with factor‐independent tumorigenic proliferation 
in humans, rodents, and dogs. Meanwhile, over 50% of canine MCTs and most of the feline 
MCTs show KITgen mutation‐independent development. Recent observations have revealed 
that not only SCF but also other cytokines and growth factors including epidermal growth 
factor, vascular endothelial growth factor, and nerve growth factor may facilitate prolifera‐
tion, differentiation, and survival of mast cells. Unfortunately, investigation on development 
of canine mast cells has been insufficient.
Figure 2. Origin and transportation of mast cell precursors. Immature mast cells without cytosolic granules are released 
from bone marrow and distributed to peripheral tissues via circulation. Final maturation of mast cells depends on 
factors and molecules expressed in microenvironment of each tissue. In the skin (the upper panel), connective tissue‐
type mast cells with rich cytosolic granules are differentiated. In mucosa of the gastrointestinal tract (the lower panel), 
mucosal‐type mast cells with few cytosolic granules are differentiated.
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3. Cellular biology of mast cells
3.1. Inflammatory responses of mast cells
Mast cells play key roles for inflammatory responses through degranulation and cyto‐
kine/chemokine production and secretion [4]. However, proteases, chemical mediators, 
and cytokines included in mast cell granules are different according to types of mast cells. 
Heterogeneity among mast cells is important to precisely understand the pathophysiolog‐
ical roles of mast cells in each tissue. Connective tissue‐type mast cells include chemical 
mediators such as histamine that has strong biologic activity on nerve fibers and blood ves‐
sels. Histamine is known as a pruritogen that induces itch sensation resulting in scratching 
behavior in humans and animals. Vasoactive effects of histamine initiate inflammation at the 
affected sites. Scratching behavior stimulates physical degranulation of mast cells leading to 
exacerbation of swelling and inflammation. Exact roles of mucosal‐type mast cells are not 
clearly demonstrated. Since numbers of mucosal‐type mast cells are increased in the gut 
with parasite infection, roles in host reaction against parasite exclusion have been proposed. 
However, factors and mechanisms that involve in antiparasite effects of mucosal‐type mast 
cells are not fully explored.
3.2. Heterogeneity of MCTs
Most MCTs in dogs are consisted with histamine‐rich connective tissue‐type mast cells. 
Steps responsible for transformation of mast cells are summarized in Figure 3. Since recep‐
tors for histamine are expressed in mucosal cells of the stomach, progression of MCTs has 
been suggested to induce gastric ulcer and serious damage on gastric function. However, 
the exact and direct association of MCTs with gastric ulcer remains unclear [5, 6]. Connective 
tissue‐type mast cells contain tryptase and chymase that possess broad protease activities. 
Particularly, tryptase has been reported to regulate neovascularization. Connective tissue‐
type mast cells can also produce growth factors for vascular endothelial cells; therefore, 
Figure 3. Malignant transformation of mast cells. For tumor formation, mast cell proliferation must be promoted by 
activation of ligand‐independent activation on growth factor receptors. Also, acquisition of resistance against apoptosis 
pathways and invasive characters may facilitate malignant expansion of MCTs.
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most of the MCTs must be rich with blood vessels. Moreover, dogs with serious MCTs show 
deficiency in blood coagulation possibly because connective tissue‐type mast cells have 
plenty of heparin in their cytosol. Canine mast cells have unique chymase whose name is 
dog mast cell protease‐3; however, its specific role has not been fully understood [7]. A mass 
formed with mucosal‐type mast cells rarely develops in the gastrointestinal tract, which 
induces dysfunction of the gut. Influence of mucosal mast cell tumor on other organs except 
the gut has not been well documented.
4. Pathology and diagnosis of MCTs
4.1. Clinical presentation, incidence, and risk factors
MCTs are characterized by the aberrant proliferation of mast cells, accounting for approxi‐
mately 20% of cutaneous tumors in dogs [8, 9]. They develop in the subcutaneous tis‐
sue and dermis in most cases, and other types of mast cell malignancies such as mast 
cell leukemia and visceral MCTs are rarely observed. They usually occur in the trunk or 
limbs and sometimes observed in the head and neck (Figure 4) [9, 10]. Because mast cells 
release proinflammatory mediators, erythema and wheal called Darier's sign are some‐
times observed. However, MCT‐specific symptoms that can distinguish MCTs from other 
tumors are rare.
Risk factors for MCTs, age, sex, breed, spay/castration, and tumor grading have been reported 
[8, 11]. Among these, most factors except sex are deeply related to its incidence [11]. Recently, 
genetic characteristics have been also investigated, showing the high correlation of KIT muta‐
tions with prognosis of dogs with MCTs [12–14]. As Mochizuki et al. [11] presented nice sum‐
mary on each factor except genetic one, we would like to focus on the genetic characteristics 
of MCTs in the following sections.
Figure 4. Representative photograph of MCT‐diagnosed dog. (A) MCT occurred in the left leg in 11‐year‐old female, 
Shiba. (B) MCT occurred in the left waist in 8‐year‐old female, Pharaoh Hound.
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4.2. Diagnosis of MCTs
Cytological or histological analyses through a fine needle aspiration or biopsy are required for 
the diagnosis of MCTs. Typically, round‐shape cells with round nuclei and with rich cytosol 
are observed. Mast cells have abundant cytosolic granules, and specific staining methods with 
toluidine blue or safranin O can identify them. However, MCTs with undifferentiated more 
malignant mast cells possess few granules. Confirmation of the swelling of draining lymph 
nodes and sometimes fine needle aspiration of the lymph node may help to determine the pres‐
ence of metastasis. Patnaik grading is mainly used pathological grading in the veterinary field 
because it is recognized as a good prognostic marker [15]. There are three pathological grades 
(grades I, II, and III), and higher grade indicates that the tumor is more malignant [15]. Several 
analyses have been revealed: the correlation between tumor grading and the c‐kit gene mutation, 
clearly showing that c‐kit mutations are more frequently observed in high‐grade tumor [12–14]. 
Therefore, analyzing c‐kit sequence can also be a prognostic marker for MCTs. In addition, ana‐
lyzing c‐kit gene is important in terms of selecting proper treatments because several molecular 
target inhibitors against KIT protein, a receptor encoded in the c‐kit gene, are currently available 
for the treatment of MCTs. Polymerase chain reaction that amplifies exon 11 and intron 11 region 
using tumor genome enables the detection of internal tandem duplications (ITDs) in the juxta‐
membrane domain, which is the most frequent type of c‐kit mutation. Recently, however, whole 
sequence of c‐kit mRNA is more common because the proportion of mutations in other region of 
KIT domain or other type of mutations in the juxtamembrane domain are not negligible. Recent 
reduction in the cost for sequencing analysis will probably boost this trend (see Section 5).
5. Neoplastic transformation of mast cells
5.1. Overview
Mast cell malignancies are observed among species, though the incidence of mast cell malig‐
nancies is much lower in human and rodents than in dogs [8, 9]. One of the well‐investigated 
mechanisms of mast cell tumorigenesis is mutations in the c‐kit gene [9, 10]. We would like to 
overview the current understandings of the mutant KIT contribution on mast cell tumorigen‐
esis as well as other tumor‐related transformations of mast cells that may correlate with their 
tumorigenesis in mast cells.
5.2. KIT mutation‐dependent neoplastic transformation
5.2.1. KIT mutations in human and rodents
KIT is a type III receptor tyrosine kinase of which ligand is stem cell factor (SCF) (Figure 5). 
It is consisted of the extracellular domain, transmembrane domain, juxtamembrane domain, 
and tyrosine kinase domain [16] (Figure 5). In human, aberrant proliferation of mast cell is 
observed in the patients of systemic/cutaneous mastocytosis, mast cell sarcoma, and mast cell 
leukemia [17]. Among them, most systemic mastocytosis occurs due to the mutations in the 
tyrosine kinase domain of KIT, especially a point mutation in Asp816 [12]. In general, SCF 
binding to KIT triggers the conformational changes in KIT and leads to the dimerization of 
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the protein, allowing the binding of adenosine triphosphate (ATP) and phosphorylation of 
tyrosine kinase domain [18]. Mutations in the tyrosine kinase domain alter the conformation 
to the one similar to its active form, thus resulting in the constitutive KIT activation even in 
the absence of either SCF binding, KIT dimerization, or ATP binding [19]. Neoplastic growth 
of mast cells is rarely observed in rodents, through currently available rodent‐derived mast 
cell lines. For example, RBL‐2H3 cells (derived from a Wistar rat) and P815 cells (derived from 
a DBA/2 mouse) express Asp817Tyr and Asp814Tyr, respectively, which correspond to the 
Asp816 mutation in human KIT [20]. As far as we know, other mechanisms that trigger rodent 
mast cell tumorigenesis have not been reported.
5.2.2. KIT mutations in dog
In contrast to human and rodents, KIT mutations in dog MCT are frequently observed in 
the juxtamembrane domain (Table 1). ITDs in the domain are the first discovered and the 
most frequent mutations in canine MCTs [21] (Table 1). Besides ITDs, other mutations in the 
juxtamembrane domain or extracellular domain have been also reported [21]. We recently 
demonstrated that most of these mutations in the extracellular or juxtamembrane domain 
cause aberrant KIT activation and neoplastic proliferation of mast cells by triggering ligand‐
independent dimerization (Ref. [22] and unpublished data). In contrast to the mutations in the 
tyrosine kinase domain, these mutations require ATP for the phosphorylation of the tyrosine 
kinase domain, providing a rationale for using ATP‐competitive small molecule inhibitors for 
suppressing the aberrant KIT activations [18, 23].
5.3. KIT mutation‐independent neoplastic transformation
Few mechanisms of mast cell tumorigenesis except KIT mutations have been identified, 
but we recently demonstrated that MCT cells produce SCF and support their growth in a 
Figure 5. Schematic diagram of KIT protein. The numbers of exon correspond to the ones in dog KIT.
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 paracrine/autocrine manner [28]. In the analyses, high SCF production was confirmed in 
 multiple clinical MCT samples [29]. It may explain the high response of clinical MCTs to KIT‐
specific molecular inhibitors even when the tumor cells express wild‐type KIT. This will be 
further discussed in the following section.
Recent approaches such as next‐generation sequencing will reveal even minor mutations 
or single nucleotide polymorphisms in neoplastic mast cells. In fact, Spector et al. [30] and 
Youk et al. [31] discovered a human mast cell leukemia‐specific mutation in several genes. 
As the cost of these approaches decreases, they will be introduced in the veterinary field, 
probably leading to the deep understanding of mast cell tumorigenesis among species. 
Another approach aiming at the control of tumor growth is modifying epigenetic status 
in tumor genome [32]. Regarding an epigenetic alteration in MCTs, Morimoto et al. [33] 
showed that DNA hypomethylation widely occurred in malignant, higher‐grade MCTs. 
Moreover, antitumor effects of AR‐42, a histone deacetylase inhibitor, on several MCT cell 
Analyzed exons Domain Exon Mutation Frequency (%) References
All Extracellular 8 417‐421ITD 8/202 (4.2%) [24]
8 Gln430Arg 1/202 (0.5%)
9 Ser479Ile 5/202 (2.5%)
9 Asn508Ile 3/202 (1.5%)
Juxtamembrane 11 555–557mutation 7/202 (3.5%)
11 ITD 25/202 (12.4%)
Tyrosine kinase 17 del826–828 1/202 (0.5%)
All Extracellular 6, 7, 8 del102AA, Thr414Ala 1/47 (2.1%) [25]
8 417‐420ITD 3/47 (6.4%)
Extracellular, 
transmembrane
9,10 ins4AA 1/47 (2.1%)
Juxtamembrane 11 del558 1/47 (2.1%)
11 Leu575Pro 1/47 (2.1%)
11 ITD 8/47 (17.0%)
Tyrosine kinase 15 del714 1/47 (2.1%)
11 Juxtamembrane 11 ITD 8/88 (9.1%) [12]
11 del 4/88 (4.5%)
11 Juxtamembrane 11 ITD 8/60 (13.3%) [13]
11 Juxtamembrane 11 ITD 7/68 (10.3%) [14]
11 Juxtamembrane 11 ITD 24/118 (20.3%) [26]
8, 9, 11 Extracellular 8 421‐429del, ins3AA 1/21 (4.8%) [27]
AA, amino acid.
Table 1. KIT mutations that have been reported in dog MCTs.
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lines as well as primary tumor cells have been demonstrated [34]. Thus, the characterization 
of epigenetic alteration is likely to be an effective approach to reveal MCT transformation.
6. Treatment and prognosis
6.1. Conventional therapies
Complete surgical removal with wide margin is the best way for solitary cutaneous 
MCTs. However, for dogs with multiple masses, metastasis, or sever invasive MCTs, 
surgical removal is sometimes incompetent. Chemotherapies have failed to overcome 
MCTs. However, to reduce tumor size, some combination chemotherapies have applied. 
Glucocorticoid is one of the most important drugs for treatment of MCTs. More than 
70% of cutaneous MCTs in dogs respond well to oral administration of glucocorticoid 
[35–37]. Expression levels of glucocorticoid receptors in MCT cells have been reported 
to associate with glucocorticoid sensitivity [37]. Glucocorticoid shows strong antitumor 
effects on MCT cells with high expression of glucocorticoid receptors. Oral administra‐
tion of glucocorticoid must be an easy and effective chemotherapy for canine MCTs. 
Since side effects induced by glucocorticoid administration will sometimes be concerned, 
clinicians must pay attention on blood chemistry data and general conditions of dog 
patients. Glucocorticoid is usually applied as a part of multidrug chemotherapies for 
MCTs. Anticancer drugs, such as vincristine, vinblastine, cyclophosphamide, and CCNU, 
have been tested for combination chemotherapies for MCTs with or without glucocorti‐
coid [38–42]. However, very little information on the chemotherapeutic response of MCTs 
can be obtained. Since recent studies have been based on small numbers of cases and 
have often included MCTs of different pathologic grades and clinical stages, data must 
be carefully evaluated [43]. Recently, adjuvant chemotherapies have been proposed in 
treatment of various cancers and sarcomas. Since neo‐adjuvant administration with glu‐
cocorticoid usually reduces mass size of MCTs, wide surgical margins will be obtained 
[37]. On the other hand, postoperative adjuvant chemotherapy is suggested to kill MCT 
cells that remain at the affected site after incomplete excision. Several trials on adjunc‐
tive chemotherapy have been reported. However, most of the adjunctive chemotherapy 
does not appear to increase survival times. Although surgical removal with radiation has 
been tested for MCTs, remarkable improvement is not provided. No difference in overall 
survival rate has been observed between dogs with MCTs receiving and not receiving 
prophylactic irradiation of the regional lymph node [44].
6.2. Molecular target therapies targeting KIT
Because aberrant activation of mutant KIT is one of the causes in mast cell tumorigenesis, 
anticancer effects of KIT inhibitors have been investigated. In fact, clinical trials that enrolled 
MCT‐diagnosed dogs have been undertaken to evaluate the efficacy of molecular targeting 
agents against KIT. We would like to overview the history of the research on KIT inhibitors 
and discuss therapeutic perspective fwor MCTs.
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The first molecular inhibitor applied to human was the imatinib mesylate, which repress 
activations of KIT, platelet‐derived growth factor receptor (PDGFR), and Bcr‐Abl [45]. It 
was first administered to the patient of gastrointestinal stromal tumor with a mutation in 
the juxtamembrane domain of KIT [46]. At around the same time, KIT mutations in canine 
MCT were first discovered [21], suggesting the possibility that KIT inhibitors can be applied 
to dog MCTs. Actually, there have been several reports that show the inhibitory effects of 
imatinib mesylate on MCTs, especially for the tumor cells with KIT mutations in either the 
extracellular domain or juxtamembrane domain [22, 47]. Based on these results from basic 
researches, some clinicians administered imatinib mesylate to MCT‐diagnosed dogs and 
obtained partial response at least in some of them [47]. However, there was no rationale 
for the administration of imatinib mesylate to MCT‐diagnosed dogs through the clinical 
trials. In contrast to that, both masitinib mesylate and toceranib phosphate are approved by 
either the Food and Drug Administration (FDA) in the United States or European Medicines 
Agency based on the results from the clinical trials enrolling MCT‐diagnosed dogs [26, 
48,49]. Basically, imatinib mesylate, masitinib mesylate, and toceranib phosphate are all 
ATP‐competitive inhibitors, and they suppress the activation of mutant KITs that require 
ATP binding for their activation.
Results of clinical trials for toceranib phosphate, which is a random double‐blind trials, are 
summarized in Table 2 [26]. In this trial, more than 150 MCT patients were enrolled. After the 
six‐week treatment, either complete response (CR) or partial response (PR) was obtained 32 
in 86 (37.2%) patients in the treatment group, while the proportion of CR/PR was only 7.9% 
(5 in 63 patients) in the placebo group. In addition, a group treated with toceranib phosphate 
following placebo‐escape, which administered toceranib phosphate after the placebo treat‐
ment, responded the agent, resulting in the CR/PR in 24 cases out of 58 (41.4%). At least in 
this trial, significant increase in severe adverse effects (grade III or IV) was not detected. In 
case of mastinib mesylate, a phase III trial was carried out in France, enrolling more than 130 
MCT patients. One‐year survival and two‐year survival were 62.1 and 39.8%, respectively, 
in the treatment group, though the ones were 36.0 and 15.0%, respectively, in the placebo 
group [49].
Interestingly, both agents showed antitumor effects even on MCTs expressing wild‐type KIT 
(Tables 2 and 3). Though the agents suppress the activation of other receptor tyrosine kinases 
All MCTs MCTs with mutant KIT MCTs without mutant KIT
Cases CR + PR Cases CR + PR Cases CR + PR
Toceranib 86 32 (37.2%) 20 12 (60.0%) 66 20 (30.3%)
Placebo 63 5 (7.9%) 9 1 (11.1%) 54 4 (7.4%)
Placebo>toceranib 58 24 (41.4%) 9 7 (77.8%) 49 17 (34.7%)
The number of the enrolled patients and the proportion of CR/PR cases are indicated.
Table 2. Summary of a clinical trial of toceranib phosphate [26].
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such as platelet‐derived growth factor receptor or vascular endothelial growth factor receptor 
2 [50, 51], aberrant activations of principal targets except KIT were not observed in our study 
using more than 30 clinical MCT tissue samples (unpublished data). Thus, it is likely that 
the data in Table 2 indicate that tumor growth in no more than 30% of MCT was dependent 
on KIT signaling even though they express wild‐type KIT. We consider that these can be at 
least partly explained by SCF autoproduction from tumor cells as described above [28, 29]. 
Though further investigations are necessary, analyses to determine the KIT activation status 
will probably be a direct diagnostic agent to accurately predict the therapeutic efficacy of KIT 
targeting inhibitors.
7. Final remarks
As described, molecular biological approaches to MCTs have started, and new findings are 
accumulating. However, some clinical researches present very limited information obtained 
from few cases. Therefore, clinicians should carefully collect information and evaluate data 
before clinical application of anticancer drugs and molecular targeting drugs to dogs with 
MCTs. It is dangerous to trust all data reported in few research reports or on few clinical 
cases. Knowledge on basic biology of mast cells will help clinicians to understand the recent 
molecular approaches to MCTs.
Author details
Yosuke Amagai1, 2 and Akane Tanaka3*
*Address all correspondence to: akane@cc.tuat.ac.jp
1 Research Fellow of the Japan Society for the Promotion of Science, Tokyo, Japan
2 Tokyo Metropolitan Institute of Medical Science, Tokyo, Japan
3 Tokyo University of Agriculture and Technology, Tokyo, Japan
All MCTs MCTs with mutant KIT MCTs without mutant KIT
1 year 2 year 1 year 2 year 1 year 2 year
Toceranib 59/95 (62.1%) 33/83 (39.8%) 17/27 (63.0%) 7/23 (30.4%) 38/62 (61.3%) 23/54 (42.6%)
Placebo 9/25 (36.0%) 3/20 (15.0%) 1/7 (14.3%) 0/6 (0%) 7/16 (43.8%) 2/12 (16.7%)
The number and proportion of the patients that survived more than 1 or 2 years are indicated.
Table 3. Summary of a clinical trial of masitinib phosphate [49].
Mast Cell Tumors
http://dx.doi.org/10.5772/65797
87
References
[1] Kitamura Y. Heterogeneity of mast cells and phenotypic change between subpopula‐
tions. Annu Rev Immunol. 1989;7:59–76. doi:10.1146/annurev.iy.07.040189.000423
[2] Brazís P, Queralt M, de Mora F, Ferrer LI, Puigdemont A. Stem cell factor enhances IgE‐
mediated histamine and TNF‐alpha release from dispersed canine cutaneous mast cells. 
Vet Immunol Immunopathol. 2000;75:97–108.
[3] Lin TY, Rush LJ, London CA. Generation and characterization of bone marrow‐derived 
cultured canine mast cells. Vet Immunol Immunopathol. 2006;113:37–52.
[4] Galli SJ, Tsai M. Mast cells: versatile regulators of inflammation, tissue remodeling, host 
defense and homeostasis. J Dermatol Sci. 2008;49:7–19.
[5] Howard EB, Sawa TR, Nielsen SW, Kenyon AJ. Mastocytoma and gastroduode‐
nal ulceration: gastric and duodenal ulcers in dogs with mastocytoma. Pathol Vet. 
1969;6:146–58.
[6] Ammann RW, Vetter D, Deyhle P, Tschen H, Sulser H, Schmid M. Gastrointestinal 
involvement in systemic mastocytosis. Gut. 1976;17:107–112.
[7] Raymond WW, Tam EK, Blount JL, Caughey GH. Purification and characteriza‐
tion of dog mast cell protease‐3, an oligomeric relative of tryptases. J Biol Chem. 
1995;270:13164–13170.
[8] Withrow and MacEwen’s small animal clinical oncology. 5th ed. Elsevier Inc.; 2013. 
p. 335–355. DOI: 10.1111/avj.12086
[9] Welle MM, Bley CR, Howard J, Rüfenacht S. Canine mast cell tumours: a review of the 
pathogenesis, clinical features, pathology and treatment. Vet Dermatol. 2008;19:321–339. 
doi:10.1111/j.1365‐3164.2008.00694.x.
[10] Blackwood L, Murphy S, Buracco P, De Vos J, Fornel‐Thibaud D, Hirschberger J, 
Kessler M, Pastor J, Ponce F, Savary‐Bataille K. European consensus document on mast 
cell tumours in dogs and cats. Vet Comp Oncol. 2012;10:e1–e29. doi:10.1111/j.1476‐ 
5829.2012.00341.x.
[11] Mochizuki H, Motsinger‐Reif A, Bettini C, Moroff S, Breen M. Association of breed and 
histopathological grade in canine mast cell tumours. Vet Comp Oncol. DOI: 10.1111/
vco.12225.
[12] Zemke D, Yamini B, Yuzbasiyan‐Gurkan V. Mutations in the juxtamembrane domain of 
c‐KIT are associated with higher grade mast cell tumors in dogs. Vet Pathol. 2002;39:529–
535. doi:10.1354/vp.39‐5‐529
[13] Webster JD, Yuzbasiyan‐Gurkan V, Kaneene JB, Miller R, Resau JH, Kiupel M. The role 
of c‐KIT in tumorigenesis: evaluation in canine cutaneous mast cell tumors. Neoplasia. 
2006;8:104–111. doi:10.1593/neo.05622
Canine Medicine - Recent Topics and Advanced Research88
[14] Amagai Y, Tanaka A, Matsuda A, Jung K, Oida K, Nishikawa S, Jang H, Matsuda H. 
Heterogeneity of internal tandem duplications in the c‐kit of dogs with multiple mast 
cell tumours. J Small AnimPract. 2013;54:377–380. doi:10.1111/jsap.12069
[15] Patnaik AK, Ehler WJ, MacEwen EG. Canine cutaneous mast cell tumor: morphologic 
grading and survival time in 83 dogs. Vet Pathol. 1984;21:469–474. doi:10.1177/03009 
8588402100503
[16] Broxmeyer HE, Maze R, Miyazawa K, Carow C, Hendrie PC, Cooper S, Hangoc G, 
Vadhan‐Raj S, Lu L. The kit receptor and its ligand, steel factor, as regulators of hemo‐
poiesis. Cancer Cells. 1991;3:480–487.
[17] Akin C, Valent P. Diagnostic criteria and classification of mastocytosis in 2014. Immunol 
Allergy Clin North Am. 2014;34:207–218. doi:10.1016/j.iac.2014.02.003
[18] Mol CD, Lim KB, Sridhar V, Zou H, Chien EY, Sang BC, Nowakowski J, Kassel DB, 
Cronin CN, McRee DE. Structure of a c‐kit product complex reveals the basis for kinase 
transactivation. J Biol Chem. 2003;278:31461–31464. doi:10.1074/jbc.C300186200
[19] Vendôme J, Letard S, Martin F, Svinarchuk F, Dubreuil P, Auclair C, Le Bret M. Molecular 
modeling of wild‐type and D816V c‐Kit inhibition based on ATP‐competitive binding of 
ellipticine derivatives to tyrosine kinases. J Med Chem. 2005;48:6194–6201. doi:10.1021/
jm050231m.
[20] Beghini A, Cairoli R, Morra E, Larizza L. In vivo differentiation of mast cells from acute 
myeloid leukemia blasts carrying a novel activating ligand‐independent c‐kit mutation. 
Blood Cells Mol Dis. 1998;24:262–270. doi:10.1006/bcmd.1998.0191
[21] London CA, Galli SJ, Yuuki T, Hu Z, Helfand SC, Geissler EN. Spontaneous canine 
mast cell tumors express tandem duplications in the proto‐oncogene c‐kit. ExpHematol. 
1999;27:689–697. doi:10.1016/S0301‐472X(98)00075‐7
[22] Amagai Y, Matsuda A, Jung K, Oida K, Jang H, Ishizaka S, Matsuda H, Tanaka A. A 
point mutation in the extracellular domain of KIT promotes tumorigenesis of mast cells 
via ligand‐independent auto‐dimerization. Sci Rep. 2015;5. doi:10.1038/srep09775
[23] Mol CD, Dougan DR, Schneider TR, Skene RJ, Kraus ML, Scheibe DN, Snell GP, Zou 
H, Sang BC, Wilson KP. Structural basis for the autoinhibition and STI‐571 inhibition 
of c‐Kit tyrosine kinase. J Biol Chem. 2004;279:31655–31663. doi:10.1074/jbc.M403319200
[24] Letard S, Yang Y, Hanssens K, Palmerini F, Leventhal PS, Guery S, Moussy A, Kinet 
JP, Hermine O, Dubreuil P. Gain‐of‐function mutations in the extracellular domain 
of KIT are common in canine mast cell tumors. Mol Cancer Res. 2008;6:1137–1145. 
doi:10.1158/1541‐7786.MCR‐08‐0067
[25] Takeuchi Y, Fujino Y, Watanabe M, Takahashi M, Nakagawa T, Takeuchi A, Bonkobara 
M, Kobayashi T, Ohno K, Uchida K. Validation of the prognostic value of histopatho‐
logical grading or c‐kit mutation in canine cutaneous mast cell tumours: a retrospective 
cohort study. Vet J. 2013;196:492–498. doi:10.1016/j.tvjl.2012.11.018
Mast Cell Tumors
http://dx.doi.org/10.5772/65797
89
[26] London CA, Malpas PB, Wood‐Follis SL, Boucher JF, Rusk AW, Rosenberg MP, Henry 
CJ, Mitchener KL, Klein MK, Hintermeister JG, Bergman PJ, Couto GC, Mauldin GN, 
Michels GM. Multi‐center, placebo‐controlled, double‐blind, randomized study of oral 
toceranib phosphate (SU11654), a receptor tyrosine kinase inhibitor, for the treatment of 
dogs with recurrent (either local or distant) mast cell tumor following surgical excision. 
Clin Cancer Res. 2009;15:3856–3865. doi:10.1158/1078‐0432.CCR‐08‐1860
[27] Marconato L, Zorzan E, Giantin M, Di Palma S, Cancedda S, Dacasto M. Concordance 
of c‐kit mutational status in matched primary and metastatic cutaneous canine mast cell 
tumors at baseline. J Vet Int Med. 2014;28:547–553. doi:10.1111/jvim.12266
[28] Amagai Y, Tanaka A, Matsuda A, Jung K, Ohmori K, Matsuda H. Stem cell factor con‐
tributes to tumorigenesis of mast cells via an autocrine/paracrine mechanism. J Leukoc 
Biol. 2013;93:245–250. doi:10.1189/jlb.0512245
[29] Amagai Y, Tanaka A, Jung K, Matsuda A, Oida K, Nishikawa S, Jang H, Ishizaka S, 
Matsuda H. Production of stem cell factor in canine mast cell tumors. Res Vet Sci. 
2014;96:124–126. doi:10.1016/j.rvsc.2013.10.014
[30] Spector MS, Iossifov I, Kritharis A, He C, Kolitz JE, Lowe SW, Allen SL. Mast‐cell leuke‐
mia exome sequencing reveals a mutation in the IgE mast‐cell receptor beta chain and 
KIT V654A. Leukemia. 2012;26:1422–1425. doi:10.1038/leu.2011.354
[31] Youk J, Koh Y, Kim J, Kim D, Park H, Jung WJ, Ahn K, Yun H, Park I, Sun C. A scien‐
tific treatment approach for acute mast cell leukemia: using a strategy based on next‐ 
generation sequencing data. Blood Res. 2016;51:17–22. doi:10.5045/br.2016.51.1.17
[32] Yoo CB, Jones PA. Epigenetic therapy of cancer: past, present and future. Nat Rev Drug 
Discov. 2006;5:37–50. doi:10.1038/nrd1930
[33] Morimoto C, Tedardi M, Fonseca I, Kimura K, Sanches D, Epiphanio T, Francisco 
Strefezzi R, Dagli M. Evaluation of the global DNA methylation in canine mast cell 
tumour samples by immunostaining of 5‐methyl cytosine. Vet Comp Oncol. 2016. 
doi:10.1111/vco.12241
[34] Lin TY, Fenger J, Murahari S, Bear MD, Kulp SK, Wang D, Chen CS, Kisseberth WC, 
London CA. AR‐42, a novel HDAC inhibitor, exhibits biologic activity against malignant 
mast cell lines via down‐regulation of constitutively activated Kit. Blood. 2010;115:4217–
4225. doi:10.1182/blood‐2009‐07‐231985
[35] Govier SM. Principles of treatment for mast cell tumors. Clin Tech Small Anim Pract. 
2003;18:103–106. doi:10.1053/svms.2003.36624
[36] Stanclift RM, Gilson SD. Evaluation of neoadjuvant prednisone administration and sur‐
gical excision in treatment of cutaneous mast cell tumors in dogs. J Am Vet Med Assoc. 
2008;232:53–62. doi:10.2460/javma.232.1.53
[37] Matsuda A, Tanaka A, Amagai Y, Ohmori K, Nishikawa S, Xia Y, Karasawa K, Okamoto N, 
Oida K, Jang H, Matsuda H. Glucocorticoid sensitivity depends on expression levels of 
Canine Medicine - Recent Topics and Advanced Research90
glucocorticoid receptors in canine neoplastic mast cells. Vet Immunol Immunopathol. 
2011;144:321–328. doi:10.1016/j.vetimm.2011.08.013
[38] McCaw DL, Miller MA, Bergman PJ. Vincristine therapy for mast cell tumors in dogs. J 
Vet Intern Med. 1997;11:375–378
[39] Dobson JM, Cohen S, Gould S. Treatment of canine mast cell tumors with prednisolone 
and radiotherapy. Vet Comp Oncol. 2004;2:132–141. doi:10.1111/j.1476‐5810.2004.00048.x
[40] Davies DR, Wyatt KM, Jardine JE, Robertson ID, Irwin PJ. Vinblastine and prednisolone 
as adjunctive therapy for canine cutaneous mast cell tumors. J Am AnimHosp Assoc. 
2004;40:124–130. doi:10.5326/0400124
[41] Thamm DH, Turek MM, Vail DM. Outcome and prognostic factors following adjuvant 
prednisolone/vinblastine chemotherapy for high‐risk canine mast cell tumor: 61 cases. J 
Vet Med Sci. 2006;68:581–587.
[42] Rassnick KM, Moore AS, Williams LE, London CA, Kintzer PP, Engler SJ, Cotter SM. 
Treatment of canine mast cell tumours with CCNU (Lomustine). J Vet Intern Med. 
1999;13:601–605.
[43] Dobson JM, Scase TJ. Advances in the diagnosis and management of cutaneous mast cell 
tumours in dogs. J Small AnimPract. 2007;48:424–431. doi:10.1111/j.1748‐5827.2007.00366.x
[44] Poirier VJ, Adams WM, Forrest LJ, Green EM, Dubielzig RR, Vail DM. Radiation ther‐
apy for incompletely excised grade II canine mast cell tumors. J Am AnimHosp Assoc. 
2006;42:430–434. doi:10.5326/0420430
[45] Heinrich MC, Griffith DJ, Druker BJ, Wait CL, Ott KA, Zigler AJ. Inhibition of c‐kit 
receptor tyrosine kinase activity by STI 571, a selective tyrosine kinase inhibitor. Blood. 
2000;96:925–932.
[46] Joensuu H, Roberts PJ, Sarlomo‐Rikala M, Andersson LC, Tervahartiala P, Tuveson D, 
Silberman SL, Capdeville R, Dimitrijevic S, Druker B. Effect of the tyrosine kinase inhibi‐
tor STI571 in a patient with a metastatic gastrointestinal stromal tumor. N Engl J Med. 
2001;344:1052–1056.doi:10.1056/NEJM200104053441404
[47] Isotani M, Ishida N, Tominaga M, Tamura K, Yagihara H, Ochi S, Kato R, Kobayashi T, 
Fujita M, Fujino Y. Effect of tyrosine kinase inhibition by imatinib mesylate on mast cell 
tumors in dogs. J Vet Int Med. 2008;22:985–988.doi:10.1111/j.1939‐1676.2008.00132.x
[48] Hahn K, Oglivie G, Rusk T, Devauchelle P, Leblanc A, Legendre A, Powers B, Leventhal 
P, Kinet J, Palmerini F. Masitinib is safe and effective for the treatment of canine mast cell 
tumors. J Vet Int Med. 2008;22:1301–1309. doi:10.1111/j.1939‐1676.2008.0190.x
[49] Hahn KA, Legendre AM, Shaw NG, Phillips B, Ogilvie GK, Prescott DM, Atwater SW, 
Carreras JK, Lana SE, Ladue T. Evaluation of 12‐and 24‐month survival rates after 
treatment with masitinib in dogs with nonresectable mast cell tumors. Am J Vet Res. 
2010;71:1354–1361. doi:10.2460/ajvr.71.11.1354
Mast Cell Tumors
http://dx.doi.org/10.5772/65797
91
[50] Pryer NK, Lee LB, Zadovaskaya R, Yu X, Sukbuntherng J, Cherrington JM, London 
CA. Proof of target for SU11654: inhibition of KIT phosphorylation in canine mast cell 
tumors. Clin Cancer Res. 2003;9:5729–5734.
[51] Le Cesne A, Blay J, Bui BN, Bouché O, Adenis A, Domont J, Cioffi A, Ray‐Coquard I, 
Lassau N, Bonvalot S. Phase II study of oral masitinib mesylate in imatinib‐naive 
patients with locally advanced or metastatic gastro‐intestinal stromal tumour (GIST). 
Eur J Cancer. 2010;46:1344–1351. doi:10.1016/j.ejca.2010.02.014
Canine Medicine - Recent Topics and Advanced Research92
